Physician profile
Anuj Chhaparia
NPI 1457747859
$1,812.68
in general payments reported to CMS, 2019-2025
14 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.00 · 2021: $53.30 · 2022: $191 · 2023: $380 · 2024: $848 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $534.98 | 2020-2025 | Stelara, Tremfya |
| Genzyme Corporation | $310.81 | 2023-2024 | |
| Abbvie INC. | $243.77 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.13 | 2023-2024 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $129.97 | 2024-2025 | Dupixent |
| Gilead Sciences, INC. | $91.29 | 2022 | |
| Merck Sharp & Dohme LLC | $60.87 | 2023-2024 | Dificid |
| Celgene Corporation | $59.97 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $41.86 | 2023-2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $41.82 | 2023-2024 | Entyvio |
| Dynavax Technologies Corporation | $41.14 | 2021 | |
| Fujifilm Healthcare Americas Corporation | $31.86 | 2024 | Fujifilm |
| Cook Medical LLC | $26.78 | 2021-2023 | Cook |
| Amgen INC. | $22.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuj Chhaparia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.